UBS
Top Five Articles on 360Dx Last Week: QuidelOrtho's Plans; Sekisui's EUAs for COVID Tests; More
Last week, readers were most interested in an update by QuidelOrtho management on the direction of the firm.
UBS Downgrades QuidelOrtho to Sell
The investment bank cited risks in the firm's guidance for respiratory test sales and in the launch of the Savanna point-of-care MDx system.
UBS Initiates Coverage of Bio-Rad Laboratories, Fulgent Genetics, Bio-Techne
The global financial services firm gave ratings of Buy, Neutral, and Buy to Bio-Rad, Fulgent, and Bio-Techne, respectively.
Experts cautioned, however, that firms will need a broader portfolio than just COVID-19 testing for sustainability in the public markets.
UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal
The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.